- Home
- AUUD vs QNRX Comparison
AUUD vs QNRX Comparison
Compare AUUD & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- QNRX
- Stock Information
- Founded
- AUUD 2012
- QNRX 2018
- Country
- AUUD United States
- QNRX United States
- Employees
- AUUD N/A
- QNRX N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- QNRX Medical/Dental Instruments
- Sector
- AUUD Technology
- QNRX Health Care
- Exchange
- AUUD Nasdaq
- QNRX Nasdaq
- Market Cap
- AUUD 4.1M
- QNRX 4.8M
- IPO Year
- AUUD 2021
- QNRX N/A
- Fundamental
- Price
- AUUD $1.98
- QNRX $14.91
- Analyst Decision
- AUUD
- QNRX
- Analyst Count
- AUUD 0
- QNRX 0
- Target Price
- AUUD N/A
- QNRX N/A
- AVG Volume (30 Days)
- AUUD 99.0K
- QNRX 858.7K
- Earning Date
- AUUD 11-06-2025
- QNRX 11-06-2025
- Dividend Yield
- AUUD N/A
- QNRX N/A
- EPS Growth
- AUUD N/A
- QNRX N/A
- EPS
- AUUD N/A
- QNRX N/A
- Revenue
- AUUD N/A
- QNRX N/A
- Revenue This Year
- AUUD N/A
- QNRX N/A
- Revenue Next Year
- AUUD N/A
- QNRX N/A
- P/E Ratio
- AUUD N/A
- QNRX N/A
- Revenue Growth
- AUUD N/A
- QNRX N/A
- 52 Week Low
- AUUD $1.85
- QNRX $5.01
- 52 Week High
- AUUD $14.60
- QNRX $54.95
- Technical
- Relative Strength Index (RSI)
- AUUD 38.57
- QNRX 65.75
- Support Level
- AUUD $1.98
- QNRX $7.19
- Resistance Level
- AUUD $2.10
- QNRX $41.80
- Average True Range (ATR)
- AUUD 0.10
- QNRX 2.89
- MACD
- AUUD 0.03
- QNRX 0.98
- Stochastic Oscillator
- AUUD 22.00
- QNRX 22.45
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.